Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

75.96USD
25 Sep 2017
Change (% chg)

$-2.60 (-3.31%)
Prev Close
$78.56
Open
$78.12
Day's High
$78.39
Day's Low
$75.55
Volume
489,334
Avg. Vol
577,931
52-wk High
$99.45
52-wk Low
$25.50

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $3,839.96
Shares Outstanding(Mil.): 48.88
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

* Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

Sep 13 2017

BRIEF-Clovis Oncology Q2 loss per share $3.88

* Clovis Oncology announces second quarter 2017 operating results

Aug 02 2017

BRIEF-Bristol-Myers, Clovis Oncology announce broad clinical collaboration

* Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types

Jul 31 2017

BRIEF-Clovis Oncology announces underwriters' option to purchase additional shares

* Clovis Oncology announces exercise in full of underwriters' option to purchase additional shares of common stock Source text for Eikon: Further company coverage:

Jun 21 2017

BRIEF-Clovis Oncology announces upsizing and pricing of public offering

* Clovis Oncology announces upsizing and pricing of public offering of common stock

Jun 20 2017

BRIEF-Clovis Oncology announces proposed offering of common stock

* Clovis Oncology announces proposed offering of common stock

Jun 19 2017

Clovis's ovarian cancer drug set for label expansion, shares soar

Clovis Oncology Inc said on Monday late-stage data on its already-approved ovarian cancer drug showed that the treatment could benefit four times as many patients, sending shares of the U.S. biotech soaring 50 percent.

Jun 19 2017

UPDATE 4-Clovis's ovarian cancer drug set for label expansion, shares soar

* Rival Tesaro's shares slip 3 pct (Adds analyst comment; updates shares)

Jun 19 2017

BRIEF-Clovis entered settlement agreement for purported class action litigation

* Clovis Oncology -on June 18,entered stipulation, agreement of settlement intended to settle purported class action litigation, Medina V. Clovis Oncology

Jun 19 2017

Clovis Oncology's cancer drug Rubraca succeeds in key study

June 19 Clovis Oncology Inc said its ovarian cancer drug Rubraca slowed disease progression in a late-stage trial involving patients with various gene mutations who had undergone initial therapy.

Jun 19 2017

Competitors

Earnings vs. Estimates